- Murayama H.
- Sakuma M.
- Takahashi Y.
- Morimoto T.
- •Remdesivir is currently used on a global scale in the treatment against COVID-19 disease.
- •Prompt recognition of remdesivir-induced hemodynamically unstable sinus bradycardia is crucial during treatment course of COVID-19.
- •Remdesivir-induced hemodynamically unstable sinus bradycardia can be supported with the use of dopamine infusion to complete its treatment course if necessary.
- 2020). Safety profile of the antiviral drug remdesivir: an update.Biomed Pharmacother. 2020; 130: 110532
- (2020, November 05). Remdesivir for the treatment of Covid-19 - final report.N Engl J Med. 2020; 383: 1813-1826
- Compassionate use of remdesivir for patients with severe Covid-19.N Engl J Med. 2020; 382: 2327-2336
- (2020, May 27). Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. PubMed Central (PMC).ACS Cent Sci. 2020; 6: 672-683
- Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.Clin Microbiol Infect. 2021; 27 (791.e5–791.e8)
- Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review.JACC Case Rep. 2020; 2: 2260-2264
- Anatomic-functional correlates of adenosine-5’-triphosphate triggered vagal depressor reflex.in: Belardinelli L. Pelleg A. Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Springer, Boston, MA1995
- Cardiac adverse events with remdesivir in COVID-19 infection.Cureus. 2020; 12: e11132
- Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.Eur J Pediatr. 2021; 180: 1627
- (2018, January 03). Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: the Japan Adverse Drug Events Study. Bps publications. Retrieved February 18, 2021, from.Pharmacol Res Perspect. 2018; 6
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury.([Updated 2019 May 4]. Available from:)
Funding Sources: The authors have no funding sources to disclose. Disclosures: The authors have no conflicts of interest to disclose.
User licenseCreative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy